Cutaneous B-Cell Lymphoma

Goyal, Amrita; LeBlanc, Robert E.; Carter, Joi B.

doi:10.1016/j.hoc.2018.08.006

Cited by 40 publications

(64 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PC-FCL, the most common PCBCL, encompasses approximately 50-60% of all PCBCL cases. PC-FCL can occur in both genders mostly in their 50s (3,6,7). The disease clinically is characterized by erythematous to violaceous plaque and tumor, with a single or multiple-lesion presentation.…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

“…Reactive T-cells and a prominent stromal component are usually detected. Cases with a diffuse growth pattern are characterized by the presence of a monotonous population of large centrocytes admixed with a variable number of centroblast (3,6,8). The neoplastic infiltrate usually spares the epidermis (3, 6).…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

“…PCBCLs have been categorized in the 2005 WHO-EORTC classification into three types: primary cutaneous marginal zone lymphoma (PC-MZL), primary cutaneous follicle center lymphoma (PC-FCL) and primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL), leg type (2). Such a classification is still accepted albeit some changes (i.e., primary cutaneous marginal zone lymphoma included within the group of extranodal marginal zone lymphomas of mucosa associated lymphoid tissue) have occurred during the past 15 years or new provisional entities have been proposed (i.e., EBV+ mucocutaneous ulcer) (3,4). Despite the difference between PC-MZL, PC-FCL and PC-DLBCL have been exhaustively investigated, an animate debate on BCL-2 expression in PC-FCL is present in the literature.…”

mentioning

confidence: 99%

See 2 more Smart Citations

BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role

et al. 2020

View full text Add to dashboard Cite

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role

et al. 2020

View full text Add to dashboard Cite

“…Primer kutanöz marjinal zon lenfoma, primer kutanöz folikül merkez hücreli lenfoma, primer kutanöz diffüz büyük B hücreli lenfoma, bacak tipi 3 başlıca primer KBHL'dir. 34…”

Section: Pri̇mer Kutanöz B Hücreli̇ Lenfomalarunclassified

Diagnosis and Staging in Primary Cutaneous Lymphomas

Yüksel¹

2020

Turkiye Klinikleri J Dermatol

View full text Add to dashboard Cite

Primer kutanöz lenfomalar, kutanöz T hücreli lenfoma (KTHL) ve kutanöz B hücreli lenfoma (KBHL)ların heterojen bir grubudur. Tanı aldıklarında çoğunlukla deriye lokalizedirler. KTHL'ler yaklaşık %80'ini, KBHL'ler ise %20'sini oluştur-maktadır. 1,2 Farklı klinik ve prognostik özelliklere sahip primer kutanöz lenfomaların tanısı için klinik, histopatoloji, immünfenotiplendirme ve gen rearranjman analizleri beraber değerlendirilmelidir. 2-4 Bu özellikleri göz önünde bulundurularak, primer kuta

show abstract

“…Their diagnosis is based on histopathology, immunohistochemistry, and staging evaluation. There are 3 types of primary (CBCL): primary cutaneous marginal zone lymphoma, primary cutaneous follicle centre lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type and NOS-type (not otherwise specified) [1]. Since these malignancies have the same morphology as their systemic counterparts, the diagnosis is one of exclusion of extracutaneous manifestation.…”

Section: Introductionmentioning

confidence: 99%

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin

Wollina¹,

Schmidt²,

Schönlebe³

et al. 2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Cutaneous B-cell lymphomas represent about 25% of all cutaneous lymphomas. Peripheral diffuse large B-cell lymphoma of the leg type is the most aggressive subtype seen mainly in elderly patients. Treatment is not standardised. CASE REPORT: An 87-year-old female patient was presented in May 2018 because of the development of painless subcutaneous nodules on the legs since late 2017. On examination, we observed up to 5 cm large erythematous nodules on the legs and a smaller plaque in the left submammary fold. The histology of a skin demonstrated tumour infiltrate that was separated from the overlying epidermis by a grenz zone. It consisted of densely packed, blastoid lymphocytic cells with numerous, and some atypical mitoses. The cells were positive for CD20, CD79A and CD5. Almost 100% of the cells were labelled with Ki67. The diagnosis of a diffuse large B-cell lymphoma (PCLBCL-LT) of the leg was confirmed. Histologic analysis of a bone marrow biopsy demonstrated a hypercellular bone marrow without malignant lymphatic infiltrates. Diagnostic ultrasound of cervical nodes and computerised tomography (CT) scans (native and with contrast medium) of head, neck and trunk excluded an extracutaneous manifestation of the PCLBCL-LT. Treatment with rituximab plus bendamustibe was initiated, but tumour progress was noted after the second course. Suggested palliative therapy with radiation and rituximab was refused. The patient died 7 months after diagnosis. CONCLUSIONS: Although some trials suggested a beneficial effect of immuno-chemotherapy, the prognosis of (PCLBCL-LT) remains poor. Standardised treatment is missing due to the relative rarity of this malignancy.

show abstract

Cutaneous B-Cell Lymphoma

Cited by 40 publications

References 59 publications

BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role

BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role

Diagnosis and Staging in Primary Cutaneous Lymphomas

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin

Contact Info

Product

Resources

About